SEC Form 4 · accession 0001231919-26-000633
Vor Biopharma Inc. · VOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
RA Capital Healthcare Fund LP
Director · 10% Owner
RA CAPITAL MANAGEMENT, L.P.
Director · 10% Owner
Peter Kolchinsky
Director · 10% Owner
Rajeev M. Shah
Director · 10% Owner
Period of report
Jun 11, 2026
Accepted (ET)
Jun 12, 2026 · 8:44 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001817229
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2,F3 | $14.09 | Jun 11, 2026 | A | 57,162 | A | — | Jun 10, 2036 | Common Stock | 57,162 | 57,162 | I |
Explanation of responses
- F1One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to Dr. Andrew Levin's continued service through each such vesting date.
- F2RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
- F3Under Dr. Levin's arrangement with the Adviser, Dr. Levin holds the option for the benefit of the Fund. Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
Remarks
Dr. Andrew Levin, a Partner and Managing Director of the Adviser, serves on the Issuer's board of directors.